Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat ocular diseases that cause vision loss and blindness.
Its lead investigational gene therapy program GT005 is an AAV2-based one-time gene therapy delivering the complement regulatory protein CFI for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GT005 is currently being evaluated in Phase II clinical trials in two different genetically defined patient populations.
Besides GT005, Gyroscope is advancing an expanded pipeline of gene therapies for retinal diseases, leveraging its proprietary OrbitTM subretinal delivery system, which is designed for precise delivery to the back of the eye.
CEO: Khurem Farooq
Location: United Kingdom, England, London
Total raised: $423.34M
Investors 5
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | Spex Capit... | spexcapita... |
| 27.03.2021 | Sofinnova ... | sofinnova.... |
| - | Syncona Pa... | synconaltd... |
| 18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 09.11.2021 | - | $60M | - |
| 29.03.2021 | Series C | $148M | - |
| 26.03.2021 | Series C | $148.49M | - |
| 03.09.2020 | Series B | $66.85M | - |
Mentions in press and media 32
| Date | Title | Description | Source |
| 18.01.2024 | VectorY appoints Khurem Farooq to Board of Directors | · CEO and Co-Founder of Aiolos Bio and previous CEO of Gyroscope Khurem Farooq joins as independent ... | forbion.co... |
| 19.04.2023 | Forbion raises €1.35 billion across two funds | • Forbion’s largest fundraising to date • €750 million raised in the final close of the Forbion Ven... | forbion.co... |
| 11.01.2023 | Novartis' CEO said gene therapy is a 'nuanced puzzle' everyo... | Vas Narasimhan, the CEO of Novartis. Reuters This story is available exclusively to Insider subscrib... | businessin... |
| 09.11.2021 | Gyroscope Therapeutics Receives Up To $60M Equity Investment... | Gyroscope Therapeutics Holdings plc, a London, UK-based clinical-stage gene therapy company focused ... | finsmes.co... |
| 08.11.2021 | Gyroscope Therapeutics Announces Sanofi Investment of Up to ... | Gyroscope Therapeutics Holdings plc (Gyroscope), a clinical-stage gene therapy company focused on di... | marketscre... |
| 08.11.2021 | Gyroscope Therapeutics Announces Sanofi Investment of up to ... | - | sofinnova.... |
| 08.11.2021 | Gyroscope Therapeutics Announces Sanofi Investment of up to ... | LONDON – 8 November 2021 – Gyroscope Therapeutics Holdings plc (Gyroscope), a clinical-stage gene th... | forbion.co... |
| 30.09.2021 | Gyroscope announces presentation of positive interim Phase I... | Gyroscope Therapeutics announces presentation of positive interim Phase I/II data for investigationa... | cic.vc/new... |
| 22.06.2021 | Gyroscope Therapeutics announces research collaboration agre... | Gyroscope Therapeutics announces research collaboration agreement with Children’s Medical Research I... | cic.vc/new... |
| 29.03.2021 | CIC participates in Gyroscope Therapeutics’ £107.8 million S... | CIC participates in Gyroscope Therapeutics’ £107.8 million Series C financing 29-03-2021 Cambridge... | cambridgen... |
Show more